Author Archives: admin


Unproved Stem Cell Clinics Proliferate in the U.S …

Patients seeking stem cell therapies for achy joints or shoulder injuries no longer need to hop a plane to Mexico or China. More than 550 clinics around the U.S. offer unproved interventions for sports injuries and conditions including autism, multiple sclerosis and Alzheimers disease. In cities like Beverly Hills or New York a prospective patient may only need to drive some 20 or 30 minutes from the center of town to find such a treatment.

This vast stem cell market has boomed in recent years, particularly for orthopedic applications such as easing joint pain or for facelifts and other cosmetic procedures. In one frequently advertised regimen a patient might have adult stem cells harvested from his own fat tissue and injected at an injury site, purportedly to speed recovery. Professional athletes including football stars Peyton Manning and Chris Johnson have reportedly used stem cell injections to help them get back onto the field.

Yet there is a darker side to the promise of these treatments. There is little systematic data about patients long-term outcomespositive or negativeand in most cases there is no scientific evidence that these costly procedures work. Many of these cellular therapies may not do much of anything but there is also the serious risk that recipients of cell injections could develop serious complications including blood clots or dangerous immune reactions, says Paul Knoepfler, a stem cell researcher at the University of California, Davis, School of Medicine and co-author of a new analysis, published Thursday in Cell Stem Cell.*

One U.S. patient traveled to China, Mexico and Argentina for stem cell therapies following a stroke and went on to develop a huge mass in his lower spinereplete with someone elses cells, according to a recent account in The New England Journal of Medicine. Without clear evidence that these procedures are safe, effective and actually tap the type of cells they claim to use, they should be avoided, Knoepfler says. (Bone marrow stem cell therapies used for cancer and blood disorder treatments, however, are widely accepted medical procedures.)

Armed with new data about the proliferation of stem cell clinics, Knoepfler and co-author, University of Minnesota bioethicist Leigh Turner, are seeking to correct the widespread belief that such procedures only happen overseas: Patients wishing to engage in stem cell tourism need only drive minutes from metropolitan areas across the U.S., not to a foreign country, they note.

Such clinics have often sidestepped heavy regulatory scrutiny, claiming they are eligible for a U.S. Food and Drug Administration exemption that applies to minimally manipulated cells. Some claim to extract a patients cells found in fat, bones or other tissues and inject them back into the same patient at a different sitesuch as a joint or a saggy chinwithin the same operation, all without substantially altering the cells. But many of these clinics also offer myriad types of stem cell treatment that would suggest they are not compliant with federal regulations, the authors wrote.

Amid this stem cell therapy explosion, the FDA recently issued draft guidance that would clarify and tighten its regulation of this area. The FDA is concerned that the hope patients have for treatments not yet proven to be safe and effective may leave them vulnerable to unscrupulous providers of stem cell treatments that are illegal and potentially harmful, FDA spokesperson Andrea Fischer said in a statement. If the proposed guidelines are enacted, the FDA would likely bring more of these clinics under its purview and regulate offerings in the same way as biological drugs. Public interest in this contentious area is undeniable: The FDA is holding a delayed public hearing on stem cell regulation this fall, after it was overwhelmed by audience sign-ups for its scheduled hearing in April.

This all should still be in the research phase without question, says Peter Rubin, a stem cell researcher who chairs the Department of Plastic Surgery at the University of Pittsburgh Medical Center and runs a clinical trial to test the use of stem cells to repair severe facial wounds and limb injuries in soldiers. We need to establish credible data around these therapies before bringing them to patients, he adds. Rubin, who was not involved in Knoepfler and Turners latest research, plans to testify at the hearing this fall.

Currently, hundreds of U.S. clinics61 percent of the businesses in the new analysismarket therapies that use fat stem cells. Although details vary between clinics, that often means the clinic gives a patient liposuction then chemically separates stem cells from the fat and centrifuges them before injecting them into an injury site to purportedly help a patient heal faster or to alleviate pain. Fat is a structural tissue, and if you break down its biological properties so it can no longer provide padding or cushioning, then it has been manipulated, Rubin says. Such procedures, he says, would likely require FDA regulation under the new proposed guidelines.

To get a new count showing exactly how widespread stem cell clinics have become, Knoepfler and Turner scoured the internet for Web sites marketing stem cell interventions. They found 351 U.S. businesses engaged in direct-to-consumer marketing of such services offered at 570 clinics. Most of the clinics were concentrated in California, Florida, Texas, Colorado, Arizona and New York, but most states had at least one. There were also certain hot spot cities with a dozen or more clinics such as Beverly Hills, New York, San Antonio and Los Angeles. The authors could not verify that the clinics truly offer what is advertised on their Web sites, the sources of their stem cells or their interactions with the FDA.

Yet what they did find, Knoepfler says, was very concerningparticularly because some of the ads targeted conditions that affect particularly vulnerable populations, including children. Nine clinics promoted stem cell treatments for autism and cerebral palsy and another 33 advertised therapies for muscular dystrophy, a disease that primarily afflicts kids. Alzheimers disease treatments were offered by 27 clinics. These are the conditions that most concern me because there is the most striking gap between the marketing claims being made and the actual evidence that is available, Turner says. In effect [the patients] are participants in unapproved human-subjects research without even realizing it.

*Editor's Note (7/11/16): This sentence was edited after posting to clarify information about the authorship of the study.

Read the rest here:
Unproved Stem Cell Clinics Proliferate in the U.S ...

Exploring the potential of stem cell-based therapy for aesthetic and plastic surgery – Newswise

Abstract:

Over the last decade, stem cell-associated therapies are widely used because of their potential in self-renewable and multipotent differentiation ability. Stem cells have become more attractive for aesthetic uses and plastic surgery, including scar reduction, breast augmentation, facial contouring, hand rejuvenation, and anti-aging. The current preclinical and clinical studies of stem cells on aesthetic uses also showed promising outcomes. Adipose-derived stem cells are commonly used for fat grafting that demonstrated scar improvement, anti-aging, skin rejuvenation properties, etc. While stem cell-based products have yet to receive approval from the FDA for aesthetic medicine and plastic surgery. Moving forward, the review on the efficacy and potential of stem cell-based therapy for aesthetic and plastic surgery is limited. In the present review, we discuss the current status and recent advances of using stem cells for aesthetic and plastic surgery. The potential of cell-free therapy and tissue engineering in this field is also highlighted. The clinical applications, advantages, and limitations are also discussed. This review also provides further works that need to be investigated to widely apply stem cells in the clinic, especially in aesthetic and plastic contexts.

Read the rest here:
Exploring the potential of stem cell-based therapy for aesthetic and plastic surgery - Newswise

Avra, Inc. Completes its Merger with Springs Rejuvenation, LLC, a Stem Cell and Anti-Aging Treatment Company – Yahoo Finance

ATLANTA, GA, Dec. 20, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Avra, Inc. (OTC PINK: AVRN), is pleased to announce that it has closed the merger with Springs Rejuvenation, LLC (https://springsrejuvenation.com). The surviving entity will be Springs Rejuvenation, Inc. (SPRINGS), a Chamblee, Georgia anti-aging and stem cell center focusing on stem cell therapy, facial rejuvenation, hair rejuvenation, non-surgical hair restoration, protein rich plasma (PRP) injections, and anti-aging treatments.

The merger documents have been filed with the State of Nevada. They have also been posted on OTC Markets along with the Consolidated financials in the last quarterly filing. On December 20, 2021, Avra, Inc. filed a Corporate Action with FINRA for a name and ticker change.

SPRINGS was founded and incorporated in the State of Georgia in May of 2019 by Dr. Charles Pereyra. The company currently has one facility located in Chamblee, Georgia. Dr. Pereyra, has assembled a very skilled team of doctors and support staff to expand the business. They include Dr. Juan P. Nieto M.D., Dr. Andrew Bernstein M.D., and Alyssa Stilwell, as executive director.

Dr. Pereyra is a practicing physician with multiple peer-reviewed publications. He earned an undergraduate degree from Cornell University, where his work with stem cells began, a Doctorate of Medicine (M.D.) from St. Georges University, and completed his residency training at New York Presbyterian Hospital Brooklyn.

Stem cell therapy is a form of regenerative medicine, designed to repair damaged cells within the body by reducing inflammation and modulating the immune system. This makes stem cell therapy a viable treatment option for a variety of medical conditions. Stem cell therapies are currently being researched throughout the country with many positive results. Showing profound outcomes in autoimmune, inflammatory, neurological, and orthopedic conditions; including Multiple Sclerosis, Lupus, Crohns disease, COPD, Parkinson's, ALS, Stroke, Congestive Heart Failure and more. Recently the FDA has begun to grant INDs for use of products containing stem cells for several conditions.

Story continues

A primary goal of the merger is to allow SPRINGS to duplicate its model of high-quality stem cell treatments throughout the United States. SPRINGS is in the process of opening a facility in Austin, Texas, in conjunction with an existing clinic, and a third location in southeast Florida. The Company plans to open a total of ten new facilities in the next twelve months.

I am excited for SPRINGS Rejuvenation to take the next step with the Avra merger. Ive always been passionate about delivering the highest quality care to my patients and making sure they have the most cutting-edge medical treatments available. For over a decade a community of only a select few has benefited from use of stem cells. With this merger we will not only expand our reach to many communities, but also drive down the cost of stem cells for everyone, making access to these remarkable treatments much easier. Im incredibly excited for the future, said Dr. Charles Pereyra.

Contact:

http://www.avrabiz.com

avrabiz21@gmail.com

See more here:
Avra, Inc. Completes its Merger with Springs Rejuvenation, LLC, a Stem Cell and Anti-Aging Treatment Company - Yahoo Finance

Stem Cell Treatment Improves Type 1 Diabetes in 1 Patient – Everyday Health

Type 1 diabetes management is a lifelong job that cant be eliminated by lifestyle changes or any currently available drugs or medical devices. Because theres no cure and no simple way to treat this chronic disease, its easy to understand why people might get excited about an experimental stem cell therapy that appears to reverse the condition even if it has worked for only a few months in a single patient.

The experimental treatment that has all the buzz right now is so early in development it doesnt even have an official name its just called VX-880. The company developing the drug, Vertex Pharmaceuticals, announced the initiation of the first human trials for this stem cell therapy in March. Then, in October, the company shared preliminary results from the first of 17 patients to be included in these trials.

All the patients in these trials have type 1 diabetes, an autoimmune disease that develops when the body attacks and destroys insulin-making islet cells in the pancreas. Insulin is a hormone that helps convert sugars in our bloodstream into energy that fuels our body. Without functional islet cells to make insulin, sugars rise to dangerously high levels in the bloodstream. To prevent this, people with type 1 diabetes have to regularly inject insulin to manage their blood sugar.

For the first patient in these VX-880 trials, 90 days of stem cell therapy dramatically reduced both blood sugar levels and the need for daily insulin shots, according to the preliminary results released by Vertex. Before starting treatment, this patient used 34 units of insulin daily and had an A1C level, which reflects average blood sugar levels over about three months, of 8.6 percent, indicating dangerously high blood sugar. After three months of stem cell therapy, the patient used 2.9 units of insulin daily and their A1C levels dropped to 7.2 percent, a level that still signifies diabetes but is improved.

VX-880 is potentially game-changing therapy, says John Buse, MD, PhD, the chief of endocrinology and the director of the Diabetes Center at the University of North Carolina School of Medicine in Chapel Hill.

But Dr. Buse, who has no connection to Vertex or these trials, also cautions that much longer trials with far more patients will be needed before we can really tell how safe or effective this therapy might be or whether it would be appropriate to use for every patient who has type 1 diabetes.

Simon Heller, MD, a diabetes researcher and a clinical professor at the University of Sheffield in the U.K. with no connection to Vertex or the trials, agrees. It has promise, but it should not be regarded as a likely treatment option, probably for some years, Dr. Heller says.

This means its far too soon to ask your doctor about whether stem cell therapy might work for you or a loved one living with type 1 diabetes.

And even if this drug does one day reach the market, its unclear how easy it would be for you to access or afford it. Insurance might not cover the treatment, and copays might be steep if it is covered. Vertex has been criticized for selling medicines that cost several hundred thousand dollars annually, a practice the company defendsas necessary to support research and development of new drugs.

It will be very expensive to start with Id guess, says Heller, who has received research funding and consulting fees from companies that sell drugs and devices to treat diabetes.

RELATED: Type 1 Diabetes May Be 2 Different Diseases, Early Study Suggests

Early work on VX-880 began more than a decade ago with a basic question: Could scientists find a way to replace dysfunctional islet cells in the pancreas with cells capable of making insulin?

Scientists thought embryonic stem cells might be the answer because they can in theory be transformed into any type of human cell in a lab. Researchers working to eradicate type 1 diabetes spent years fine-tuning a process to convert embryonic stem cells into functional islet cells. This work is complex because investigators needed to figure out how islet cells were created naturally inside the pancreas, then sort out how to program embryonic stem cells to grow into islet cells in the lab, a process thats unique for every type of cell in the body.

Stem cell therapies involve replacing diseased or dysfunctional cells with healthy ones. All these lab experiments eventually led to VX-880, an infusion of replacement islet cells derived from embryonic stem cells. This is not only a potential breakthrough in the treatment of type 1 diabetes, its also one of the first practical demonstrations that embryonic stem cells might indeed be used to make treatments that replace dysfunctional cells in this case islet cells in the pancreas, says one of the scientists who developed the drug, Doug Melton, PhD, the codirector of the Harvard Stem Cell Institute in Cambridge, Massachusetts, and an investigator at the Howard Hughes Medical Institute in Chevy Chase, Maryland.

Unlike other treatments for type 1 diabetes, VX-880 gives patients functional islet cells so they can make their own insulin, giving them enough of this hormone to regulate their blood sugar. In theory, this could mean people with type 1 diabetes no longer need to check their blood sugar levels and inject insulin several times a day to stay in a healthy range.

RELATED: How to Develop a Type 1 Diabetes Plan With Your Childs School

If this experimental drug lives up to its early promise, the infused replacement islet cells would provide the patient with the natural factory to make their own insulin, Dr. Melton said in a statement released by the Harvard Stem Cell Institute in October after preliminary results from tests in one patient came out.

One wrinkle to this approach is that patients would also need to take immunosuppressants the same medicines given to people who receive organ donations to stop the body from rejecting the new islet cells. Patients would potentially require lifelong therapy with both VX-880 and immunosuppressants. Long-term risks of immunosuppressants include susceptibility to serious infections, according to the Cleveland Clinic.

Scientists are also studying how to use whats known as encapsulated islet cells (a different form of cells than those used in VX-880) that are surrounded by a membrane that helps prevent the body from mounting an immune system attack to reject them. These encapsulated islet cells have the potential to be used without immunosuppressants, saidBastiano Sanna, PhD, the executive vice president and chief of cell and genetic therapies at Vertex, in the statement released by the company with its preliminary trial results.

For now, however, any optimism about the potential to eradicate type 1 diabetes needs to be tempered by the reality that we know how well VX-880 works only in a single patient for a handful of months, says Heller.

One big unanswered question at this point is whether this experimental stem cell therapy can safely and reliably provide the body with working islet cells that can ramp up and scale back insulin production so that levels of the hormone rise and fall in concert with the amount of sugars circulating in the bloodstream, Heller notes. This process of detecting how much insulin is needed is crucial for helping to maintain healthy blood sugar levels over time.

With just one person it is much too early to say whether this will turn out to be a realistic treatment, but it might, Heller says. We really need to see the results of a trial involving a largish number of patients for a time longer than 90 days.

RELATED: 11 Celebrities Living With Type 1 Diabetes

More here:
Stem Cell Treatment Improves Type 1 Diabetes in 1 Patient - Everyday Health

Avra, Inc. Completes its Merger with Springs Rejuvenation, LLC, a Stem Cell and Anti-Aging Treatment Company – GlobeNewswire

ATLANTA, GA, Dec. 20, 2021 (GLOBE NEWSWIRE) -- viaNewMediaWire --Avra, Inc. (OTC PINK: AVRN), is pleased to announce that it has closed the merger with Springs Rejuvenation, LLC (https://springsrejuvenation.com). The surviving entity will be Springs Rejuvenation, Inc. (SPRINGS), a Chamblee, Georgia anti-aging and stem cell center focusing on stem cell therapy, facial rejuvenation, hair rejuvenation, non-surgical hair restoration, protein rich plasma (PRP) injections, and anti-aging treatments.

The merger documents have been filed with the State of Nevada. They have also been posted on OTC Markets along with the Consolidated financials in the last quarterly filing. On December 20, 2021, Avra, Inc. filed a Corporate Action with FINRA for a name and ticker change.

SPRINGS was founded and incorporated in the State of Georgia in May of 2019 by Dr. Charles Pereyra. The company currently has one facility located in Chamblee, Georgia. Dr. Pereyra, has assembled a very skilled team of doctors and support staff to expand the business. They include Dr. Juan P. Nieto M.D., Dr. Andrew Bernstein M.D., and Alyssa Stilwell, as executive director.

Dr. Pereyra is a practicing physician with multiple peer-reviewed publications. He earned an undergraduate degree from Cornell University, where his work with stem cells began, a Doctorate of Medicine (M.D.) from St. Georges University, and completed his residency training at New York Presbyterian Hospital Brooklyn.

Stem cell therapy is a form of regenerative medicine, designed to repair damaged cells within the body by reducing inflammation and modulating the immune system. This makes stem cell therapy a viable treatment option for a variety of medical conditions. Stem cell therapies are currently being researched throughout the country with many positive results. Showing profound outcomes in autoimmune, inflammatory, neurological, and orthopedic conditions; including Multiple Sclerosis, Lupus, Crohns disease, COPD, Parkinson's, ALS, Stroke, Congestive Heart Failure and more. Recently the FDA has begun to grant INDs for use of products containing stem cells for several conditions.

A primary goal of the merger is to allow SPRINGS to duplicate its model of high-quality stem cell treatments throughout the United States. SPRINGS is in the process of opening a facility in Austin, Texas, in conjunction with an existing clinic, and a third location in southeast Florida. The Company plans to open a total of ten new facilities in the next twelve months.

I am excited for SPRINGS Rejuvenation to take the next step with the Avra merger. Ive always been passionate about delivering the highest quality care to my patients and making sure they have the most cutting-edge medical treatments available. For over a decade a community of only a select few has benefited from use of stem cells. With this merger we will not only expand our reach to many communities, but also drive down the cost of stem cells for everyone, making access to these remarkable treatments much easier. Im incredibly excited for the future, said Dr. Charles Pereyra.

http://www.avrabiz.com

avrabiz21@gmail.com

See the original post:
Avra, Inc. Completes its Merger with Springs Rejuvenation, LLC, a Stem Cell and Anti-Aging Treatment Company - GlobeNewswire

Global Regenerative Medicine Market is Expected to Reach USD 57.08 Billion by 2027, Growing at a CAGR of 11.27% Over the Forecast Period. -…

DUBLIN--(BUSINESS WIRE)--The "Global Regenerative Medicine Market Size, Share & Trends Analysis Report by Product (Cell-based Immunotherapies, Gene Therapies), by Therapeutic Category (Cardiovascular, Oncology), and Segment Forecasts, 2021-2027" report has been added to ResearchAndMarkets.com's offering.

The global regenerative medicine market size is expected to reach USD 57.08 billion by 2027, growing at a CAGR of 11.27% over the forecast period.

Recent advancements in biological therapies have resulted in a gradual shift in preference toward personalized medicinal strategies over the conventional treatment approach. This has resulted in rising R&D activities in the regenerative medicine arena for the development of novel regenerative therapies.

Furthermore, advancements in cell biology, genomics research, and gene-editing technology are anticipated to fuel the growth of the industry. Stem cell-based regenerative therapies are in clinical trials, which may help restore damaged specialized cells in many serious and fatal diseases, such as cancer, Alzheimer's, neurodegenerative diseases, and spinal cord injuries.

For instance, various research institutes have adopted Human Embryonic Stem Cells (hESCs) to develop a treatment for Age-related Macular Degeneration (AMD).

Constant advancements in molecular medicines have led to the development of gene-based therapy, which utilizes targeted delivery of DNA as a medicine to fight against various disorders.

Gene therapy developments are high in oncology due to the rising prevalence and genetically driven pathophysiology of cancer. The steady commercial success of gene therapies is expected to accelerate the growth of the global market over the forecast period.

Regenerative Medicine Market Report Highlights

Key Topics Covered:

Market Variables, Trends, & Scope

Competitive Analysis

Covid-19 Impact Analysis

Regenerative Medicine Market: Product Business Analysis

Regenerative Medicine Market: Therapeutic Category Business Analysis

Regenerative Medicine Market: Regional Business Analysis

Companies Mentioned

For more information about this report visit https://www.researchandmarkets.com/r/kovhgl

Go here to read the rest:
Global Regenerative Medicine Market is Expected to Reach USD 57.08 Billion by 2027, Growing at a CAGR of 11.27% Over the Forecast Period. -...

Stem cell therapy holds immense promise for the treatment of patients with non-healing ischemic leg wounds – Ibcworldnews

Mysuru

An 88-year-old gentleman presented to Manipal Hospital Mysore with blackish discoloration of the heel of left foot. He was diabetic & was on regular treatment for the same. For the current problem, he had already received several medications including intra venous antibiotics with little improvement. Upon examination he was detected to have Critical Limb Ischemia (CLI) with gangrene of heel of left foot. Large number of such patients end up with amputation of leg. Our aim in such situation is to first try to save the limb. Amputation should be the last resort when everything else fails. Said Dr. Upendra Shenoy Cardiothoracic and Vascular Surgeon Manipal Hospital Mysore, while giving details about the patient. While addressing the media Dr. C B Keshavamurthy Consultant Interventional Cardiology, Manipal Hospital Mysore said, Patients angiogram showed diffuse disease in all blood vessels of the leg with critical blocks in many areas.

We performed angioplasty on the limb. The procedure improved the blood supply to the limb, but additional treatment was required to restore blood circulation to the foot and toes. Dr. Shenoy and team decided to implement stem cell therapy, hybrid procedure of peripheral angioplasty with stem cell injection. First of its kind procedure in Mysore. Stem cell therapy involves the injection of stem cells obtained from the bone marrow of healthy individuals.

These stem cells can transform themselves into different tissues according to the requirement. In this case, the stem cells stimulate the formation of new blood vessels, said Dr Upendra Shenoy while explaining about the therapy. Dr Shenoy further added, On the day after angioplasty, we injected the stem cell into the calf muscles of the patient.

The dose depends upon the weight of the patient. If the weight is below 60 kg, the doctor injects about 150 million stem cells. In patients with more than 60 kg, the dose is about 200 million.

Go here to read the rest:
Stem cell therapy holds immense promise for the treatment of patients with non-healing ischemic leg wounds - Ibcworldnews

Importance of stem cells-Past, present and future – Express Healthcare

Dr Pradeep Mahajan, Regenerative Medicine Researcher, StemRx Bioscience Solutions highlights the importance and other aspects of stem cell technology

Globally, we are seeing a change in the type of age-specific, chronic, debilitating diseases. Thus, the manner in which we diagnose and treat such diseases is also seeing a paradigm shift. From empirical use of drugs to target-specific treatments, we are now advancing towards molecular dysfunction-based therapies.

I have been in the field of clinical medicine and surgery for over 3 decades now and I have always been fascinated by new research. Among the substantial advances in the healthcare field, I believe regenerative medicine and cell-based therapy have been game changers. We saw hematopoietic stem cells being used to treat blood cancers and related diseases for over 3-4 decades. Now we are seeing an expansion in the applications of stem cells in treating various acute, chronic, lifestyle, and even genetic and congenital diseases. The need arose because conventional medicine is gradually losing potency in treating diseases and patients are often left at the mercy of nature to take its course.

With increasing knowledge of stem cells, the trend to utilise the endogenous repair mechanisms of the human body gained popularity. Cells, growth factors and other biological products, when present at the right site; at the right moment, stimulate the natural healing mechanisms of the body and aid in management of health conditions. Cell-based therapy thus marked the beginning of a new era in regenerative medicine.

Stem cells are present in several tissues, namely, embryo, umbilical cord, placenta, as well as adult body tissues. These are the master cells of the body that have roles in development of the body, repairing and regenerating injured tissues (at a cellular level), and maintaining homeostasis even in an healthy individual. Of course, we have all heard of ethical issues regarding the use of embryonic stem cells as well as their tumor-forming issue. Regarding umbilical cord stem cells, the trend of banking this tissue has just begun; therefore, the majority of us would not have the umbilical cord as a source of stem cells. Keeping in mind these aspects, researchers started focusing on adult stem cells that can be derived from different tissues of the human body. The common sources are bone marrow, fat tissue, peripheral blood, and teeth, among others. The chief advantage is that, the source being autologous, the therapy is safe and is not associated with side effects.

Coming to the diseases that can be treated using stem cellswe have just scratched the tip of the iceberg. There are several health conditions that plague mankindarthritis, diabetes, nerve-related conditions, traumatic injuries, etc. Conventionally, one would be prescribed medications (often for prolong periods or even for their lifetime) or be advised surgery. Nonetheless, in several cases, the quality of life of a patient is compromised. The various properties of stem cells help reduce swelling in the body, regulate the immune system, enhance the functioning of other cells, and create a healthy environment for health cells to thrive. Through this, one can target a myriad of pathologies at the molecular level, in a minimally/non-invasive manner.

Patients today are quite aware of the benefits of regenerative medicine and cell based therapy, but there is still a long distance to cover. Countries are promoting research and development in the field of regenerative medicine and cell-based therapy. Research advances pertaining to introducing products with cell and scaffold based technology through tissue engineering are underway. Bioactive scaffolds that are capable of supporting activation and differentiation of host stem cells at the required site are being developed. In the future, it will be possible to use human native sites as micro-niche/micro-environment for potentiation of the human bodys site-specific response. Another breakthrough in the field of cell-based therapy is immunotherapy that aims to utilise certain parts of a persons immune system and stimulate them to fight diseases such as cancer.

The scope of cell-based therapy is endless. All we need is more research, awareness, and implementation to permit reach of the treatment to every stratum of the society. Soon, we will talk about treating diseases with cells and not pills and knives!

Go here to read the rest:
Importance of stem cells-Past, present and future - Express Healthcare

BioRestorative Therapies, Inc. Releases Year-End Message – BioSpace

MELVILLE, N.Y., Dec. 20, 2021 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (the Company" or BioRestorative) (NASDAQ:BRTX), a life sciences company focused on adult stem cell-based therapies, today released the following year-end message.

As we reach the end of 2021, we are inspired by the many healthcare workers and biopharmaceutical companies that have worked to combat the COVID-19 pandemic. This year has been environmentally difficult, but we have seen incredible advancements in our sector which have reinforced the importance of our mission to become a clinical stage company. Since our emergence from Chapter 11 in 2020, we have sought to take positive steps at BioRestorative Therapies with the goal of making it a preeminent cell therapy company. During 2021, we achieved important transformational milestones, which created meaningful intrinsic value and advanced us toward our stated strategic goals.

In November of this year, we closed on a $23 million capital raise and concurrently listed our securities on the Nasdaq Capital Market. This is a very significant development as we are now fully funded to complete our Phase 2 trial for our lead clinical candidate, BRTX-100, for the treatment of chronic lumbar disc disease (CLDD.) During this process, we have attracted many new institutional fundamental investors as well as some retail investors. With that accomplished, I would like to briefly discuss the status of our programs and the opportunities that lie ahead of us.

BRTX-100 is our lead program for the treatment of CLDD, one of the leading causes of lower back pain. Our solution is a one-time injection of 40 million mesenchymal stem cells derived from a patients own bone marrow and expanded ex vivo before re-injection. Two things make us optimistic about this program. First, in connection with our IND filing, we referred the FDA to prior human clinical studies from different institutions that demonstrated the safety/feasibility of using mesenchymal stem cells to treat disc orders. This data not only enabled us to accelerate our clinical program and initiate a Phase 2 trial, but we believe it substantially reduces risk in offering compelling guidance on the use of cell-based interventions to treat lower back pain. Second, our manufacturing of BRTX-100 involves the use of low oxygen conditions, which ensures that the cells have enhanced survivability after introduction into the harsh avascular environment of the injured disc which has little or no blood flow. The benefits of this process are significant and are illustrated well in our recent Journal of Translational Medicine publication. Our approach is akin to transplant medicine in which specific cell types are used to replace the ones which have been lost to disease. We believe that transplanting targeted cells can offer a more attractive safety profile and potentially an improved clinical outcome. We remain optimistic that we will see significant positive clinical outcomes as we proceed with our clinical trial.

The most significant milestones we achieved in 2021 include:

Our 2022 objectives include the initiation of enrollment for our BRTX-100 clinical trial, the development of our overall product profiles via manufacturing and delivery system improvements, and the entering into of technology validation and enabling partnerships to accelerate our clinical timelines.

Some of the events and milestones that we hope to accomplish in 2022 include:

This is an exciting time to be part of the BioRestorative family. As we enter 2022 with a well-capitalized balance sheet to fully fund our Phase 2 trial, we look to accelerate our research and development pipeline. We do not take for granted that our technologies give us an opportunity to make a profound impact on the everyday lives of many people. We are grateful for the opportunity to validate such technologies; it is what we do and what we believe is the center of our core competencies.

Visit our website at http://www.biorestorative.com for more information about BioRestorative.

Thank you to the BioRestorative family for your loyalty and ongoing support.

I wish you and all those near and dear to you a wonderful Holiday Season and the very best for 2022 and beyond.

Very truly yours,

Lance Alstodt President, CEO and Chairman of the Board

About BioRestorative Therapies, Inc.

BioRestorative Therapies, Inc. (www.biorestorative.com) develops therapeutic products using cell and tissue protocols, primarily involving adult stem cells. Our two core programs, as described below, relate to the treatment of disc/spine disease and metabolic disorders:

Disc/Spine Program (brtxDISC): Our lead cell therapy candidate, BRTX-100, is a product formulated from autologous (or a persons own) cultured mesenchymal stem cells collected from the patients bone marrow. We intend that the product will be used for the non-surgical treatment of painful lumbosacral disc disorders or as a complementary therapeutic to a surgical procedure. The BRTX-100 production process utilizes proprietary technology and involves collecting a patients bone marrow, isolating and culturing stem cells from the bone marrow and cryopreserving the cells. In an outpatient procedure, BRTX-100 is to be injected by a physician into the patients damaged disc. The treatment is intended for patients whose pain has not been alleviated by non-invasive procedures and who potentially face the prospect of surgery. We have received authorization from the Food and Drug Administration to commence a Phase 2 clinical trial using BRTX-100 to treat chronic lower back pain arising from degenerative disc disease.

Metabolic Program (ThermoStem): We are developing a cell-based therapy candidate to target obesity and metabolic disorders using brown adipose (fat) derived stem cells to generate brown adipose tissue (BAT). BAT is intended to mimic naturally occurring brown adipose depots that regulate metabolic homeostasis in humans. Initial preclinical research indicates that increased amounts of brown fat in animals may be responsible for additional caloric burning as well as reduced glucose and lipid levels. Researchers have found that people with higher levels of brown fat may have a reduced risk for obesity and diabetes.

FORWARD-LOOKING STATEMENTS

This letter contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events or results to differ materially from those projected in the forward-looking statements as a result of various factors and other risks, including, without limitation, those set forth in the Company's latest Form 10-K filed with the Securities and Exchange Commission (SEC) and other filings made with the SEC. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this letter are made as of the date hereof and the Company undertakes no obligation to update such statements.

CONTACT:

Email: ir@biorestorative.com

See the rest here:
BioRestorative Therapies, Inc. Releases Year-End Message - BioSpace

Corneal epithelial differentiation of human pluripotent stem cells generates ABCB5+ and Np63+ cells with limbal cell characteristics and high wound…

Background

Differentiation of functional limbal stem cells (LSCs) from human pluripotent stem cells (hPSCs) is an important objective which can provide novel treatment solutions for patients suffering from limbal stem cell deficiency (LSCD). Yet, further characterization is needed to better evaluate their immunogenicity and regenerative potential before clinical applications.

Human PSCs were differentiated towards corneal fate and cryopreserved using a clinically applicable protocol. Resulting hPSC-LSC populations were examined at days 1011 and 2425 during differentiation as well as at passage 1 post-thaw. Expression of cornea-associated markers including PAX6, ABCG2, Np63, CK15, CK14, CK12 and ABCB5 as well as human leukocyte antigens (HLAs) was analyzed using immunofluorescence and flow cytometry. Wound healing properties of the post-thaw hPSC-LSCs were assessed via calcium imaging and scratch assay. Human and porcine tissue-derived cultured LSCs were used as controls for marker expression analysis and scratch assays at passage 1.

The day 2425 and post-thaw hPSC-LSCs displayed a similar marker profile with the tissue-derived LSCs, showing abundant expression of PAX6, Np63, CK15, CK14 and ABCB5 and low expression of ABCG2. In contrast, day 1011 hPSC-LSCs had lower expression of ABCB5 and Np63, but high expression of ABCG2. A small portion of the day 1011 cells coexpressed ABCG2 and ABCB5. The expression of class I HLAs increased during hPSC-LSCs differentiation and was uniform in post-thaw hPSC-LSCs, however the intensity was lower in comparison to tissue-derived LSCs. The calcium imaging revealed that the post-thaw hPSC-LSCs generated a robust response towards epithelial wound healing signaling mediator ATP. Further, scratch assay revealed that post-thaw hPSC-LSCs had higher wound healing capacityin comparison to tissue-derived LSCs.

Clinically relevant LSC-like cells can be efficiently differentiated from hPSCs. The post-thaw hPSC-LSCs possess functional potency in calcium responses towards injury associated signals and in wound closure. The developmental trajectory observed during hPSC-LSC differentiation, giving rise to ABCG2+ population and further to ABCB5+ and Np63+ cells with limbal characteristics, indicates hPSC-derived cells can be utilized as a valuable cell source for the treatment of patients afflicted corneal blindness due to LSCD.

View original post here:
Corneal epithelial differentiation of human pluripotent stem cells generates ABCB5+ and Np63+ cells with limbal cell characteristics and high wound...